Why Medtronic (MDT) Is Buying Intersect ENT (XENT) For $1.1 Billion

By Amit Chowdhry ● Aug 7, 2021
  • Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion. 

Medtronic plc (NYSE:MDT) — a global leader in medical technology — announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will buy all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. The boards of directors of both companies have unanimously approved the transaction.

Medtronic’s acquisition of Intersect ENT expands on the company’s portfolio of products used during ear, nose, and throat procedures. And the complementary product lines and customer base will further Medtronic’s efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT’s PROPEL and SINUVA sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. 

By combining the products with Medtronic’s navigation, powered instruments, and existing tissue health products, the company intends to offer a broader suite of solutions to assist surgeons in treating CRS patients. Intersect ENT’s PROPEL implant – which is used primarily in hospitals and ambulatory surgery centers – is a bioabsorbable, drug-eluting implant inserted after sinus surgery to keep passageways open and deliver an anti-inflammatory steroid to the sinuses.

And SINUVA implants are primarily used in the office environment for the treatment of recurrent sinus obstruction due to nasal polyps in adult patients who have had ethmoid sinus surgery.

Following the close, the deal is expected to be accretive to Medtronic’s weighted average market growth rate (WAMGR) and to be neutral to Medtronic’s adjusted earnings per share in the first 12 months and accretive thereafter. And the acquisition is expected to close toward the end of Medtronic’s current fiscal year, subject to the satisfaction of customary closing conditions, including receipt of regulatory clearances and approval by Intersect ENT’s stockholders.

KEY QUOTES:

“This acquisition directly aligns with our commitment to delivering continuous innovation that helps ENT patients. Intersect ENT’s sinus implants are clinically proven to offer relief and healing to patients suffering from chronic rhinosinusitis. Combining this innovative technology with our established global presence and sales infrastructure will allow us to broaden our capabilities while expanding access to these valuable therapies.”

— Vince Racano, president of the ENT business, which is part of the Neuroscience Portfolio at Medtronic

“This is an exciting day for patients suffering from CRS. After years of pioneering technology to help patients heal following sinus surgery, we welcome the integration of Intersect ENT’s portfolio into Medtronic. We are looking forward to the global impact we can make as part of Medtronic, bringing these essential products to more patients than ever before. Thank you to our Intersect ENT employees – without you, we would not have reached this important step in our evolution.”

— Thomas West, president and CEO of Intersect ENT